Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Variations in pharmacy-based transition-of-care activities in the United States: a national survey.

Kern KA, Kalus JS, Bush C, Chen D, Szandzik EG, Haque NZ.

Am J Health Syst Pharm. 2014 Apr 15;71(8):648-56. doi: 10.2146/ajhp130510.

PMID:
24688039
2.

Prevalence and risk factors associated with vancomycin-resistant Staphylococcus aureus precursor organism colonization among patients with chronic lower-extremity wounds in Southeastern Michigan.

Tosh PK, Agolory S, Strong BL, Verlee K, Finks J, Hayakawa K, Chopra T, Kaye KS, Gilpin N, Carpenter CF, Haque NZ, Lamarato LE, Zervos MJ, Albrecht VS, McAllister SK, Limbago B, Maccannell DR, McDougal LK, Kallen AJ, Guh AY.

Infect Control Hosp Epidemiol. 2013 Sep;34(9):954-60. doi: 10.1086/671735. Epub 2013 Jul 26.

PMID:
23917910
3.

Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA.

Pasquale TR, Jabrocki B, Salstrom SJ, Wiemken TL, Peyrani P, Haque NZ, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, File TM Jr; IMPACT-HAP Study Group.

Int J Infect Dis. 2013 Jun;17(6):e398-403. doi: 10.1016/j.ijid.2012.12.013. Epub 2013 Feb 1.

4.

Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.

Haque NZ, Arshad S, Peyrani P, Ford KD, Perri MB, Jacobsen G, Reyes K, Scerpella EG, Ramirez JA, Zervos MJ.

J Clin Microbiol. 2012 May;50(5):1640-4. doi: 10.1128/JCM.06701-11. Epub 2012 Feb 15.

5.

Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.

Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, Kett DH; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group.

Clin Ther. 2012 Jan;34(1):149-57. doi: 10.1016/j.clinthera.2011.12.013.

PMID:
22284995
6.

Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.

Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ.

Clin Infect Dis. 2012 Jan 1;54(1):51-8. doi: 10.1093/cid/cir764. Epub 2011 Nov 21.

PMID:
22109947
7.

Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene.

Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, Scerpella EG, Mangino JE, Kett DH, Ramirez JA; IMPACT-HAP Study Group.

Clin Infect Dis. 2011 Oct;53(8):766-71. doi: 10.1093/cid/cir541. Epub 2011 Aug 31.

PMID:
21880581
8.

Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.

Moore CL, Lu M, Cheema F, Osaki-Kiyan P, Perri MB, Donabedian S, Haque NZ, Zervos MJ.

Antimicrob Agents Chemother. 2011 Oct;55(10):4581-8. doi: 10.1128/AAC.00115-11. Epub 2011 Aug 8.

9.

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study.

Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.

Lancet Infect Dis. 2011 Mar;11(3):181-9. doi: 10.1016/S1473-3099(10)70314-5. Epub 2011 Jan 20.

PMID:
21256086
10.

Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.

Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, Cano E, Mangino JE, Kett DH, Ramirez JA, Zervos MJ; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.

Chest. 2010 Dec;138(6):1356-62. doi: 10.1378/chest.09-2453. Epub 2010 Jun 17.

PMID:
20558550
11.

USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit.

Moore CL, Osaki-Kiyan P, Perri M, Donabedian S, Haque NZ, Chen A, Zervos MJ.

J Clin Microbiol. 2010 Jun;48(6):2307-10. doi: 10.1128/JCM.00409-10. Epub 2010 Mar 24. No abstract available.

12.

Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections.

Moore CL, Hingwe A, Donabedian SM, Perri MB, Davis SL, Haque NZ, Reyes K, Vager D, Zervos MJ.

Int J Antimicrob Agents. 2009 Aug;34(2):148-55. doi: 10.1016/j.ijantimicag.2009.03.004. Epub 2009 Apr 25.

PMID:
19394801
13.

Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA).

Haque NZ, Davis SL, Manierski CL, Vager D, Donabedian SM, Perri MB, Sabbagh R, Cheema F, Zervos MJ.

Int J Antimicrob Agents. 2007 Jul;30(1):72-7. Epub 2007 Apr 10.

PMID:
17428640
14.

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection.

Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, Haque NZ, Speirs K, Muder RR, Robinson-Dunn B, Hayden MK, Zervos MJ.

J Clin Microbiol. 2007 Jun;45(6):1705-11. Epub 2007 Mar 28.

Supplemental Content

Loading ...
Support Center